Artelo Biosciences Advances ART26.12 FABP5 Inhibitor Toward Multiple Ascending Dose Study in Q4 2026

Artelo Biosciences' first-in-class FABP5 inhibitor ART26.12 is moving toward a multiple ascending dose study, with enrollment targeted for Q4 2026, a timeline that will sharpen the analgesic pipeline's manufacturing and supply-chain planning requirements for any future development partners. The compound's Phase 1 single ascending dose data showed predictable pharmacokinetics and tolerability across all dose levels tested, providing a stable pharmacological basis for the next study stage.

Preclinical findings published in the European Journal of Pain reported broad analgesic activity across multiple pain models, including modulation of pain-related pathways and reduction of pro-inflammatory mediators. For drug development teams tracking non-opioid, non-steroidal analgesic candidates, ART26.12's mechanism distinguishes it from existing classes, though Phase 1 multiple ascending dose data will be the next material checkpoint for assessing clinical viability.

On the oncology-support side, Artelo's ART27.13 program continues to generate interim Phase 2 data in cancer-related anorexia, with reported improvements in body weight, lean body mass, and physical activity. The company is simultaneously exploring the asset as a potential GLP-1 companion therapy and in a fully third-party-funded Phase 2 glaucoma study, an arrangement that limits Artelo's direct capital exposure on that arm of the program.

Financially, Artelo reported a net loss of $3.0 million for Q1 2026, compared to $2.4 million in Q1 2025. R&D expenses declined to $0.8 million from $1.4 million year-over-year, while G&A expenses rose to $1.9 million from $1.0 million over the same period. Cash and investments stood at $10.3 million as of March 31, 2026, following a recent capital raise the company states provides runway through multiple upcoming clinical milestones. Strategic partnering discussions are described as active across both programs.

The Q4 2026 multiple ascending dose enrollment start for ART26.12 represents the next measurable inflection point against which pipeline progress and cash consumption can be assessed.

Source: Artelo Biosciences, Inc. via GlobeNewswire, May 14, 2026.